Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ropidoxuridine,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Shuttle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims at the formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. Ropidoxuridine is used to sensitize rapidly growing cancer cells and selective histone deacetylase inhibitors to sensitize cancer cells.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 03, 2023
Lead Product(s) : Ropidoxuridine,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Shuttle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement